Phreesia PHR 深 滬
等待開盤 09-17 09:30:00 美东时间
10.24
-0.110
-1.06%
華盛通- 最 高10.33
- 今 開10.27
- 成交量 55.38万股
- 最 低 10.1604
- 昨 收 10.35
- 總市值 6.36亿
- 52周最高 24.245
- 市盈率 靜 273.07
- 換手率 0.89%
- 52周最低 7.77
- 委 比 -59.15%
- 總股本 6207.09万
- 歷史最高 81.592
- 量 比 0.85
- 振 幅 1.64%
- 歷史最低 7.77
- 每 手 1
- 風險率 5.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Raymond James Downgrades Phreesia to Market Perform
Raymond James analyst John Ransom downgrades Phreesia (NYSE:PHR) from Outperform to Market Perform.
09-08 23:36
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Phreesia Files Shelf Prospectus For Offering; Size Not Disclosed
https://www.sec.gov/Archives/edgar/data/1412408/000162828026060497/phreesia-sx3asr2026.htm
09-04 04:57
Transcript: Phreesia Q2 2027 Earnings Conference Call
Phreesia (NYSE:PHR) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. Access...
09-03 05:31
Phreesia shares are trading lower after the company reported mixed Q2 financial results.
Phreesia shares are trading lower after the company reported mixed Q2 financial results.
09-03 04:21
Phreesia Affirms FY2027 Sales Guidance of $510.000M-$520.000M vs $515.008M Est
Phreesia (NYSE:PHR) affirms FY2027 sales outlook from $510.000 million-$520.000 million to $510.000 million-$520.000 million vs $515.008 million estimate.
09-03 04:12
Phreesia Q2 EPS $0.03 Misses $0.10 Estimate, Sales $129.458M Beat $129.069M Estimate
Phreesia (NYSE:PHR) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.10 by 70 percent. This is a 200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $129.458 million which beat t...
09-03 04:08
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Needham Reiterates Buy on Phreesia, Maintains $14 Price Target
Needham analyst Ryan MacDonald reiterates Phreesia (NYSE:PHR) with a Buy and maintains $14 price target.
08-31 18:10
Phreesia证券欺诈诉讼及其未被提及的问题
菲瑞西亚（PHR）证券集体诉讼首席原告申请截止日期为7月13日，2025年5月至2026年3月期间买入PHR股票并蒙受重大损失的投资者可在截止前向法院申请主导该...
06-30 07:13
